Search jobs
16-Mar-2021
Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection
Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection
Brighton, United Kingdom, 15 March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it has entered into a Non-Clinical Evaluation Agreement (NCEA) with the US government’s National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, to evaluate the preclinical safety of a dermal formulation of XF-73. Under NIAID’s suite of preclinical services, NIAID-funded contractors will conduct these clinically enabling safety studies.